James Dugan, MD
Hematology · Winston Salem, NCNPI 1326304353
Payments from drug & device makers
Across 390 payments — averaging $9449.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$3M
- AbbVie$280K
- Astellas Pharma Global Development$159K
- Janssen Research & Development, LLC$122K
- Rigel Pharmaceuticals, Inc.$52K
- E.r. Squibb & Sons, L.L.C.$34K
- plus $42K from 29 others
Across 4 payments — averaging $289.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1K
- Astellas Pharma Global Development$69
What the payments were for
- Consulting fees$43,48022%
- Speaking & faculty fees$119,01759%
- Travel & lodging$30,06615%
- Food & beverage$7,7364%
- Education$1570%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 7 | $2,995,085 |
| AbbVie | 113 | $280,274 |
| Astellas Pharma Global Development | 111 | $159,271 |
| Janssen Research & Development, LLC | 15 | $121,818 |
| Rigel Pharmaceuticals, Inc. | 37 | $51,975 |
| E.r. Squibb & Sons, L.L.C. | 22 | $34,404 |
| Immunogen, Inc. | 1 | $19,971 |
| Sobi, Inc | 8 | $6,941 |
| Agios Pharmaceuticals, Inc. | 1 | $2,400 |
| Servier Pharmaceuticals LLC | 1 | $2,400 |
| Bristol Myers Squibb | 11 | $1,927 |
| Seagen Inc. | 1 | $1,650 |
| Morphosys, US Inc. | 1 | $1,455 |
| Astellas Pharma US Inc | 4 | $1,225 |
| Janssen Scientific Affairs, LLC | 2 | $978 |
| Sanofi | 10 | $783 |
| Karyopharm Therapeutics Inc. | 5 | $461 |
| Johnson & Johnson | 3 | $230 |
| Gilead(2 entities) | 5 | $196 |
| Genentech, Inc. | 1 | $177 |
| Amgen | 2 | $175 |
| AstraZeneca(2 entities) | 3 | $171 |
| GSK | 3 | $171 |
| Pfizer | 3 | $151 |
| Incyte Corporation | 3 | $134 |
| Sanofi-aventis U.S. LLC | 3 | $132 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $124 |
| Genentech USA, Inc. | 3 | $113 |
| Jazz Pharmaceuticals Inc. | 1 | $103 |
| Spectrum Pharmaceuticals Inc. | 1 | $97 |
| Adaptive Biotechnologies Corporation | 3 | $81 |
| Beone Medicines USA, Inc. | 2 | $46 |
| Tempus AI, Inc | 1 | $25 |
| Merck | 1 | $22 |
| Syndax Pharmaceuticals, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,685,185 in reported general payments places this provider in the 90th percentile of 65 hematology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 105 | $1,570,296 |
| PomalystPomalidomide | 44 | $859,662 |
| VenclextaVenetoclax | 105 | $737,247 |
| CalquenceAcalabrutinib Maleate | 37 | $514,619 |
| IdhifaEnasidenib Mesylate | 15 | $506,515 |
| BrukinsaZanubrutinib | 25 | $357,514 |
| NinlaroIxazomib Citrate | 23 | $285,903 |
| DopteletAvatrombopag Maleate | 16 | $229,219 |
| SprycelDasatinib | 23 | $221,378 |
| ImbruvicaIbrutinib | 13 | $199,094 |
| GleevecImatinib Mesylate | 11 | $116,186 |
| XareltoRivaroxaban | 29 | $23,409 |
| EliquisApixaban | 14 | $13,466 |
| Posaconazole | 14 | $12,699 |
| ValacyclovirValacyclovir Hcl | 261 | $10,388 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid, Idhifa | $1,927 | $2,076,811120 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $34,404 | $1,081,04067 claims |
| AbbVieVenclexta | $280,274 | $737,247105 claims |
| AstraZenecaCalquence | $171 | $514,61937 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $124 | $285,90323 claims |
| NovartisGleevec | $2,995,085 | $116,18611 claims |
| Johnson & JohnsonXarelto | $230 | $23,40929 claims |
| PfizerEliquis | $151 | $13,46614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 65 hematology providers in North Carolina.
Other hematology in Winston Salem
- Franklin ChenWinston Salem$1.3M
- Konstantinos LontosWinston Salem$467K
- Jan MorebWinston Salem$113K
- John OwenWinston Salem$7K
- Kathleen ElliottWinston Salem$7K
- Alan Zausner SkarbnikCharlotte$9.8M
- Ryan JacobsCharlotte$8.5M
- Sascha TuchmanDurham$6.8M
- Manisha BhutaniCharlotte$6.8M
- Peter VoorheesCharlotte$5.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.